Medication description: Ethylenediaminetetraacetic acid disodium salt (Dinatrii aethylendiamintetraacetas)
DINATRIC SALT ETHYLENE DIAMOND TETAUAC ACID (Dinatrii aethylendiamintetraacetas).
Synonyms: Trilon B, EDTU, Calsol, Dinatriumedetat, Endrate, Irgalon, Kalex, Prochelate, Questrex, Sequestrene, Sequestrol, Sodium edetate, Tetracemindinatriumi, Titriplex, Trilon B, Tyclarosol, Versene, etc.
White crystalline powder, soluble in water, practically insoluble in alcohol and ether.
The disodium salt of EDTU (Na 2 EDTU) refers, as well as thetacin-calcium and pentacin, to the group of chelating agents.
Able to form complex compounds with various cations, including calcium ions. This makes it possible to use EDTA in diseases accompanied by excessive deposition of calcium salts in the body, in pathological ossification of the skeleton, arthritis with deposition of salts, calcium deposition in muscles, kidneys, vein walls, scleroderma, etc. Sometimes used to treat some forms of ectopic arrhythmias, especially arising from overdose of cardiac glycosides.
When used for therapeutic purposes, it must be borne in mind that the therapeutic effect without side effects occurs with the slow introduction of the drug into the blood stream; Under these conditions, the interaction with serum calcium is slow and the serum calcium does not significantly decrease, since the loss is compensated for by mobilizing calcium from tissues, in particular from bone tissue, and excessive deposits in the organs. With the rapid introduction of the drug, physiological mechanisms do not have time to eliminate the decrease in serum calcium levels and acute tetany may develop.
EDTA, in connection with the ability to bind calcium ions, is also used as an anticoagulant for blood preservation.
The main indications for the use of EDT are diseases with symptoms of calcification: dermatomyositis, scleroderma, ossifying myositis.
For therapeutic purposes, a solution of EDT is used intravenously. Dilute 5% solution of EDTA in an isotonic solution of sodium chloride or 5% glucose solution.
Enter at a speed of 8 - 12 drops per minute. Adults and children over 10 years old are administered 10 ml of 5% EDTA solution, diluted in 200 ml of solvent; children under 10 years old - 5 ml of 5% solution of EDTA, diluted in 100 ml of solvent.
The course of treatment consists of 15 injections: administered in cycles of 5 days daily with 7-day breaks (only 3 cycles per course). Treatment courses are repeated after 4 - 6 months.
During treatment, it is necessary to monitor the content of calcium and phosphorus in the blood and daily urine. Diet during treatment should contain a reduced amount of calcium.
With the introduction of the drug into a vein, sometimes there is a burning sensation that can spread throughout the body and persist for 1 to 2 hours after the end of the infusion.
With rapid administration, tetany can develop; in these cases, it is necessary to stop the administration of the drug.
EDTA is contraindicated in hemophilia, low blood clotting, hypocalcemia, kidney and liver diseases.
Product form: 5% solution in 5 or 10 ml ampoules (Solutio Dinatrii aethylendiamintetraacetatis 5% of injectionibus) in a package of 10 ampoules.
Storage: List B.